The advanced renal cell carcinoma therapeutics market is projected to expand steadily throughout the forecast period, supported by increasing cancer prevalence, rising utilization of combination ...
The 2026 ASCO annual meeting featured a kidney cancer session and a presentation by Dr. Juan Ruiz Banobre discussing ultrasensitive ctDNA detection and molecular clearance as a prognostic and ...
The approval of belzutifan, an oral hypoxia-inducible factor-2 alpha inhibitor, provides a new option for patients with advanced renal cell carcinoma (RCC) following treatment with a programmed death ...
Survival is good for patients when renal cell carcinoma (RCC) is caught early, but options for advanced disease present challenges, explained Alan Tan, MD, an assistant professor in the Division of ...
Development and Validation of an 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography–Based Imaging Score to Predict 12-Week Life Expectancy in Advanced Chemorefractory Colorectal ...
Findings from the LITESPARK-005 trial showed a statistically significant improvement in progression free survival with belzutifan compared with everolimus. The Food and Drug Administration (FDA) has ...
Expert perspectives on the decision-making process for selecting frontline systemic therapy for patients with advanced renal cell carcinoma. Chandler H. Park, M.D.: One of the toughest parts of being ...
Diagnosed With Advanced Renal Cell Carcinoma: Why You May Want a Second Opinion, and How to Find One
Many people with cancer can benefit from a second medical opinion. Those with advanced renal cell carcinoma (RCC), who are likely considering multiple treatment options, if not combinations of ...
Credit: Getty Images. Belzutifan is a hypoxia-inducible factor inhibitor. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental News Drug Application (sNDA) for ...
COPENHAGEN — First-line treatment of metastatic kidney cancer could be set for change, with new results showing that the oral tyrosine kinase inhibitor cabozantinib (Cabometyx, Exelixis) significantly ...
Genitourinary oncologists discuss the safety and efficacy of IO/TKI and IO/IO combination therapies in advanced renal cell carcinoma. Tian Zhang, M.D., M.H.S.: In terms of front-line therapies, as we ...
MADRID -- Treatment with the hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan (Welireg) in advanced, heavily pretreated kidney cancer led to superior outcomes when compared with an older ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results